Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis

Table 4

Pooled RR of adverse events in FD patients receiving acotiamide versus placebo by Mantel-Haenszel fixed-effect model.

Groups	Number of trials [reference]	Number of patients	RR; 95% CI	value	Test of heterogeneity
					value
Serum prolactin increased^a	4 [11, 16, 25]	1709	1.59; 0.79–3.21	0.190	0.120	40%
Alanine aminotransferase increased	4 [11, 16, 25]	1709	1.42; 0.82–2.47	0.210	0.710	0%
Triglycerides increased	3 [16, 25]	1667	0.89; 0.69–1.14	0.360	0.810	0%
-glutamyltransferase increased	3 [16, 25]	1667	1.01; 0.66–1.54	0.970	0.630	0%
White blood cell count increased	1 [25]	892	0.65; 0.34–1.27	0.210	NA	NA
Serum bilirubin increased	1 [25]	892	1.04; 0.55–1.95	0.910	NA	NA
Constipation	2 [16]	775	0.99; 0.34–2.92	0.980	0.620	0%
Diarrhoea	3 [16, 25]	1667	1.34; 0.81–2.23	0.250	0.860	0%
Nasopharyngitis	1 [25]	892	0.93; 0.61–1.42	0.750	NA	NA

^aMantel-Haenszel random-effects model.
CI, confidential interval; FD, functional dyspepsia; NA, not applicable; and RR, risk ratio.